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Abstract
Introduction: The best care setting for patients with inflammatory bowel disease [IBD] may be 
in a dedicated unit. Whereas not all gastroenterology units have the same resources to develop 
dedicated IBD facilities and services, there are steps that can be taken by any unit to optimise 
patients’ access to interdisciplinary expert care. A series of pragmatic recommendations relating 
to IBD unit optimisation have been developed through discussion among a large panel of 
international experts.
Methods: Suggested recommendations were extracted through systematic search of published 
evidence and structured requests for expert opinion. Physicians [n  =  238] identified as IBD 
specialists by publications or clinical focus on IBD were invited for discussion and recommendation 
modification [Barcelona, Spain;  2014]. Final recommendations were voted on by the group. 
Participants also completed an online survey to evaluate their own experience related to IBD units.
Results: A total of 60% of attendees completed the survey, with 15% self-classifying their centre 
as a dedicated IBD unit. Only half of respondents indicated that they had a defined IBD treatment 
algorithm in place. Key recommendations included the need to develop a multidisciplinary team 
covering specifically-defined specialist expertise in IBD, to instil processes that facilitate cross-
functional communication and to invest in shared care models of IBD management.
Conclusions: Optimising the setup of IBD units will require progressive leadership and willingness 
to challenge the status quo in order to provide better quality of care for our patients. IBD units are 
an important step towards harmonising care for IBD across Europe and for establishing standards 
for disease management programmes.
Keywords:  Crohn’s disease; decision making; delivery of healthcare; interdisciplinary communication; tertiary care centres; ulcerative colitis
1. Introduction
The long-term course of inflammatory bowel disease [IBD] is 
often characterised by symptomatic flare-ups and intermittent 
periods of remission. However, many patients develop a chronic, 
perpetual activity that can be only partially controlled and that 
leads to debilitating complications. IBD is typically managed by 
gastroenterologists, with input from colorectal surgeons as required. 
Other specialties involved in the care for complex cases include 
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://crea-
tivecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided 
the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
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rheumatology, dermatology, ophthalmology, nutrition specialists, 
gynaecology/urology and psychology. However, the multifaceted and 
complex nature of these diseases, together with the impact they have 
on patient quality of life, mean that they may best be managed in a 
dedicated IBD unit by a multidisciplinary team [MDT] with exper-
tise in different aspects of the conditions.1,2
In addition, most therapies that have been approved to treat 
IBD induce a long-term [ie greater than 1  year] response in only 
4050% of patients, with the percentage being even smaller if suc-
cess is defined as achieving remission or disease control. The clinical 
studies that led to approval of such IBD therapies provide little or no 
evidence on how to optimise outcome through choice of drugs, dose 
modification or combination treatment. Large, multidisciplinary 
IBD units may offer greater expertise and aspects of quality control 
when considerable unmet medical needs have to be addressed.
Some excellent integrated models of care for IBD have been sug-
gested.3 However, not all gastroenterology centres can command the 
resources for large units. Nevertheless, there are steps that can be 
taken by any unit to create a clinical setting that optimises care for 
patients with IBD with regard to accurate diagnosis, proactive moni-
toring/disease management and timely introduction of appropriate 
treatment by expert healthcare professionals.
The purpose of this current initiative was to develop a series of 
pragmatic recommendations that could be adopted by any hospital 
or IBD unit to optimise quality of care.
2. Methods
In October 2013, a Steering Committee [EL, ID, SG, and SS] 
developed a preliminary series of recommendations relating to:
1. Role of the colorectal surgeon in an IBD unit
2. Establishment of an MDT
3. Structure of the IBD unit
4. Best practice procedures in an IBD unit
5. Best practice patient support in the IBD unit
6. Development and training of the MDT.
Three gastroenterology researchers [LM, CR, and Dörthe Schuldt] 
were nominated by the Steering Committee to conduct a struc-
tured evaluation of the published evidence on these recommenda-
tions. PubMed, EMBASE, and the Cochrane Library were searched 
using pre-defined search strings and limits, with additional hand-
searching of references as required. In January 2014, preliminary 
recommendations and related scientific evidence were presented 
to 238 physicians who had been identified as IBD specialists by 
publications or clinical focus on IBD [invited from 41 countries] 
at a meeting in Barcelona, Spain. Participants were asked to com-
plete an online survey before the meeting to evaluate their own 
experience in relation to dedicated IBD units, and then working 
groups were formed to discuss recommendations. Refinements 
were proposed as necessary according to published evidence and 
expert opinion. Meeting participants voted on their level of agree-
ment with each refined recommendation using a scale of 1 to 9 
[where 1 =  strong disagreement and 9 =  strong agreement]. If ≥ 
75% of participants scored within the 7–9 range, then the recom-
mendation was deemed to be agreed upon. If < 75% of partici-
pants scored within this range, the recommendation was debated 
and revised, and a second vote was taken. Each recommendation 
could be voted on a maximum of three times. Results of the online 
survey are presented here, followed by the findings of the literature 
review and agreed recommendations.
3. Results
3.1. Current status of IBD centres in selected 
European care settings
A total of 142/238 attendees [60%] completed the online survey 
before the meeting. Responses are shown in Table 1. Of particular 
note, only 15% of responding attendees were currently employed in 
a dedicated IBD unit [self-defined assessment], although the major-
ity of attendees reported that they had relevant specialists working 
in their hospital/clinic and participants had been selected to repre-
sent gastroenterologists with particular clinical interest and expertise 
in IBD care. Educational resources and support for patients with 
IBD within hospitals/clinics were relatively low, with only 34% of 
respondents indicating that they had a patient support programme 
available. Whereas the majority of respondents reported that they 
had a treatment goal for each IBD patient, only half indicated that 
they had a defined IBD treatment algorithm in place.
3. 2. Recommendations for IBD unit optimisation
3.2.1. Role of the colorectal surgeon in an IBD unit
Surgery rates in IBD have decreased with improved therapy:4 the 
10-year cumulative risk of surgery remains around 15% in ulcera-
tive colitis [UC] and 47% in Crohn’s disease [CD].5 The UK IBD 
Standards Group recommends that surgery be performed by an expe-
rienced colorectal surgeon who is a core member of the IBD team.6 
Other groups also recommend that IBD units include a surgeon or 
surgical team with IBD experience.7 Indeed, several studies in popu-
lations undergoing colorectal surgery have shown that postoperative 
mortality and morbidity are decreased relative to the operating sur-
geon’s volume of cases/experience8,9,10,11 or subspecialty training.11 In 
particular, patients requiring pouch / salvage pouch surgery or more 
complex CD procedures should have these operations carried out by 
specialists with appropriate training and experience.6,7
It is essential that there is close and structured integration of 
medical and surgical management to determine the right time for 
surgery and to prevent postoperative complications or recurrence.1 
This may take the form of a parallel or joint medical–surgical clinic 
in an IBD unit.6,7 One prospective study in patients undergoing ileal 
pouch-anal anastomosis reported that joint patient care by a colo-
rectal surgeon and an IBD-oriented gastroenterologist enhanced 
patient satisfaction compared with separate visits to gastroenterol-
ogy or colorectal surgery clinics.12
3.2.2. Establishment of the MDT
The complexity, heterogeneity, costs, patient impact and lifelong 
nature of IBD lends itself to being ideally managed by an MDT 
Role of the colorectal surgeon in an IBD unit: recommenda-
tions:
3.2.1.1. The surgeon should have an interest in IBD and 
appropriate experience. 213/227 [94%] agreed
3.2.1.2. There should be structured interaction between the 
gastroenterologist and the colorectal surgeon. 206/225 [92%] 
agreed
3.2.1.3 There should be joint decision making before and 
after surgery, involving the gastroenterologist, colorectal sur-
geon and IBD patient. 213/226 [94%] agreed
3.2.1.4. Pouch surgery should be performed in a regional 
centre capable of managing pouch-related complications. 
207/227 [91%] agreed
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that includes a number of specialties and support services.1,2 Several 
groups have provided recommendations on the composition of a 
core IBD team.6,7 IBD specialist nurses provide patients with com-
plication management, education, advocacy, and physical and emo-
tional support.13,14 Responsibilities may also include performing 
patient reviews, encouraging treatment adherence, running a tele-
phone clinic, laboratory follow-ups, and prescription repeats.13,15,16 
Several studies have reported improvements in patient outcomes 
when a dedicated IBD nurse was involved in patient care, including 
fewer hospital admissions,17,18,19 reduced length of hospital stay,16,18 
and temporary improvements in health-related quality of life.20
Malnutrition is common in patients with IBD, particularly those 
with CD. Nutritional care includes prevention or treatment of mal-
nutrition and micronutrient deficiencies and, in children, promotion 
of optimal growth and development. Easy accessibility to a nutri-
tionist or nutritional support team for comprehensive assessment 
and management has been recommended by several groups,6,21 with 
the importance of specific knowledge of IBD highlighted in a survey 
of gastroenterologists.15 Furthermore, specialists in stoma care have 
also been cited as important in the MDT.6,7,21
Endoscopy and cross-sectional imaging are essential for diag-
nostic confirmation of IBD and are also important monitoring 
tools over the course of the disease to document flare-ups, evalu-
ate treatment efficacy, detect complications, identify postoperative 
recurrence, and perform colorectal cancer surveillance.22,23 Close 
cooperation between the gastroenterologist and the endoscopist 
and/or radiologist is essential to ensure timely and accurate diag-
nosis and the most appropriate methods of ongoing monitoring. 
An international survey of gastroenterologists has recommended 
continuity of care by the same endoscopist.21 Other recommenda-
tions are that endoscopic and radiology units are available in the 
same hospital as the IBD unit and that patients should be man-
aged by endoscopists and radiologists with specific training or a 
special interest in IBD.6,7 An IBD expert pathologist is important in 
the work-up of IBD patients, particularly for differential diagnosis 
and special situations inherent to therapy [such as the risk of cyto-
megalovirus infection reactivation].24 Furthermore, the pathologist 
is fundamental to detecting precancerous lesions as part of a colo-
rectal cancer surveillance programme.
Psychological distress, depression, and anxiety may trigger dis-
ease relapse; therefore, appropriate psychological interventions 
could improve treatment efficacy.25 Furthermore, the input of a 
social worker with IBD experience may be useful in supporting 
patients and their caregivers with social services.26
However, it is not always possible to have all these personnel in 
one unit, owing to resourcing and financial constraints. IBD units 
should try to work with other departments in the same hospital 
or neighbouring centres to share services in a productive and cost-
effective way. Importantly, however, the staff involved should have 
IBD experience so that the collaboration is effective and efficient. 
A higher level of professional satisfaction has been reported among 
health professionals who treat IBD patients exclusively relative to 
those who treat all patients with gastrointestinal disease.27
The UK IBD Standards Group recommends that scheduled 
weekly MDT meetings be held to discuss complex patients identi-
fied by the team, with formal recording of attendance and outcomes 
in the hospital notes.6 This may involve networking with external 
healthcare professionals involved in the patient’s care. This group 
also recommends that the MDT should agree on which member of 
the team will discuss any decisions with the patient. In addition, 
the majority of patients with IBD desire active involvement in the 
decision-making process of their disease management.28,29,30 Indeed, 
the needs and views of the patient should be presented as part of the 
MDT discussion. It may even be appropriate to include the patient as 
part of the MDT meeting, although no literature was found to sup-
port this concept in IBD. Patient- and demand-directed care, which 
includes a direct telephone line for patients to a specialised nurse, 
appointments scheduled in accordance with expected needs, and 
emergency appointments available daily, has been shown to improve 
patient outcomes.31
Table 1. Online survey responses regarding work setting, resourc-
es and practice [n = 142; completed prior to meeting].
Question Respondents, %
In what setting do you work for the majority of time?
 IBD unit 15%
 Gastroenterology unit 27%
 Gastroenterology/hepatology unit 42%
 General hospital 16%
Which specialists currently work at your hospital/clinic?
 Colorectal surgeon 87%
 IBD-specialist nurse 62%
 Nutritionist 83%
 Stoma specialist 62%
 Psychologist/social services 66%
 Imaging specialist to interpret scans/images 85%
Which resources do you have at your hospital?
 Endoscopy suite 97%
 Imaging suite 88%
 Practice guidelines for screening/diagnosis 
of IBD
72%
 Therapeutic algorithms for treatment of 
IBD
75%
 Practice guidelines for monitoring IBD 65%
 IBD patient education 56%
 IBD patient support programme 34%
 Regular internal assessments/audits 37%
Do you assign a prognosis for every patient  
diagnosed with IBD
 Yes 23%
 No 77%
Do you set a treatment goal for every patient with IBD
 Yes 88%
 No 12%
Does your hospital have a defined treatment  
algorithm in place for the treatment of IBD?
 Yes 49%
 No 51%
Establishment of the MDT: recommendations:
3.2.2. In addition to a gastroenterologist and a colorec-
tal surgeon, the MDT should include an IBD-specialist nurse, 
nutritionist, stoma specialist, radiologist, endoscopist, patholo-
gist, psychologist and social worker. 178/224 [79%] agreed
3.2.2.2. Each MDT member should have IBD experience. 
181/225 [81%] agreed
3.2.2.3. There should be structured interaction between the 
members of the MDT. 210/227 [93%] agreed
3.2.2.4 The MDT should adopt a patient-centred approach 
that takes patient preferences and convenience into account. 
195/223 [87%] agreed
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3.2.3. Structure of the IBD unit
There is some evidence in the literature that specialist IBD clinics 
may provide better care than the general gastroenterology clinics.2 
IBD represents a spectrum of challenging conditions that is best 
managed by a MDT that includes access to ancillary services with 
specific experience in treating patients with IBD.1,7 Included in the 
ancillary services should be access to IBD-specific primary care, given 
that general practitioners typically see few IBD patients and may be 
uncomfortable with treating them.15,32,33,34 Transition from paediatric 
to adult services needs to be carefully managed to allow an appropri-
ate psychosocial development trajectory.35,36 Fertility, pregnancy, and 
breastfeeding may all be affected by IBD, and patients may often 
be misinformed about fertility-related issues37,38 thereby benefiting 
from appropriate access to obstetrics and gynaecology services. 
Furthermore, although there is a high prevalence of other immune-
mediated inflammatory diseases [IMIDs] in patients with IBD,39 
many never consult an appropriate specialist40 and potentially miss 
opportunities for accurate diagnosis and appropriate management.
Optimisation of any IBD unit needs to take into consideration 
the physical layout of the clinic. Several groups have outlined the 
ideal requirements for facilities [including toilets] and diagnostic and 
therapeutic equipment [including imaging facilities].6,7,25
There are conflicting data as to whether hospital volume influ-
ences mortality and morbidity rates,8,10,11,41,42,43,44 although a number 
of studies suggest that there is a survival advantage in high-volume 
IBD admission centres, particularly in patients undergoing surgery. 
Several studies have defined high-volume IBD admission centres 
to include around 150 IBD-related hospitalisations each year.43,44 
A consensus conference sponsored by several German national soci-
eties involved in IBD used a nominal group process method to define 
‘high-volume’ as a necessity for a certain threshold of IBD outpa-
tients treated.45
Current treatment algorithms for IBD include use of biological ther-
apy as standard in patients with aggressive disease or those refractory to 
conventional treatments. Clinical experience with these agents is impor-
tant in ensuring optimal therapeutic effect and minimizing adverse 
events.46,47 Furthermore, patients who do not respond to approved 
treatments should have the opportunity to participate in clinical trials.
3.2.4. Best practice procedures in an IBD unit
There is very little published evidence on the impact of documented 
guidelines on efficiency or clinical outcomes. Several groups have 
recently published recommendations on important process and out-
come quality indicators or performance measures in IBD care.22,48,49,50
3.2.5. Best practice patient support in the IBD unit
Formal IBD patient education improves knowledge, perceived knowl-
edge, and patient satisfaction.51,2,53 In addition, several studies have 
shown that patient information recall can improve treatment adher-
ence.54,55 Telemedicine applications [such as teleconsulting and tele-
education] have been shown to improve treatment adherence, quality 
of life, and disease knowledge.56 Structured or shared decision-mak-
ing support for patients and caregivers may lead to more effective 
and efficient decision making, decreased psychosocial distress, and, 
ultimately, improved outcomes.28,29,30,57 In addition, patient organisa-
tions may be useful in providing education, advocacy, and support to 
further improve the quality of life of patients with IBD:
Structure of the IBD unit: recommendations:
3.2.3.1 The unit should have an MDT specialising in IBD. 
213/225 [95%] agreed
3.2.3.2 Where appropriate, the unit should coordinate care 
with the following ancillary care providers: primary care prac-
titioner; paediatric transition team; obstetrics/gynaecology spe-
cialist; and IMID specialists [eg rheumatologist, dermatologist]. 
Patients should be able to access emergency IBD care through the 
unit and intensive care facilities, if required. 175/219 [80%] agreed
3.2.3.3 The unit should have dedicated space for all MDT 
activities. 189/224 [84%] agreed
3.2.3.4 The unit should have adequate facilities for the 
specific needs of IBD patients, such as adequate toilets, wash-
ing rooms and preparation rooms [e.g. stoma care]. 191/222 
[86%] agreed
3.2.3.5 The unit should have an endoscopy suite, or struc-
tured access to a nearby endoscopy suite. 183/226 [81%] 
agreed
3.2.3.6 The unit should have access to imaging [eg high-def-
inition computed tomography or magnetic resonance imaging, 
or ultrasound where used]; a formalised discussion with a radi-
ology specialist with IBD experience should be incorporated. 
209/224 [81%] agreed
3.2.3.7 The unit should manage a high volume of IBD 
patients. 176/221 [80%] agreed
3.2.3.8 The unit should have experience in the adminis-
tration of all approved drugs for IBD, including anti-tumour 
necrosis factor [TNF] therapy. 205/219 [94%] agreed [Edited 
to add: anti-integrin therapy was commercially unavailable at 
the time the recommendations were developed.]
3.2.3.9 The unit should have access to clinical studies in 
IBD. 198/218 [91%] agreed
Best practice procedures in an IBD unit: recommendations:
3.2.4.1 The unit’s practice guidelines should be clearly 
documented, and include: standardised referral data; diagno-
sis, and baseline assessment; entry points to care [referral from 
primary care, transition from paediatric to adult care, hospi-
talisation criteria, referral to surgery]; therapeutic algorithms; 
disease activity monitoring; and monitoring for side effects and 
adherence. 204/223 [92%] agreed
3.2.4.2 Regular self-assessment of the unit should be con-
ducted to see how quality of care and service may be improved. 
212/224 [95%] agreed
3.2.4.3 There should be systems in place to capture and 
respond to patient feedback on their experience and to give 
patients a voice in the continuous development of the IBD unit. 
170/224 [76%] agreed
3.2.4.4 The unit should keep thorough and accurate elec-
tronic patient records adapted to the IBD care unit. 182/226 
[80%] agreed
Best practice support in an IBD unit: recommendations:
3.2.5.1 The unit should have a structured patient support 
programme that includes the following: appropriate patient 
education materials; patient education delivery and follow-up; 
and patient–MDT and patient–patient interaction opportunities 
[e.g. patient forum, patient ‘open days’]. 198/227 [87%] agreed
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3.2.6. Development and training of the MDT
Guideline adherence is not always optimal among IBD-treating phy-
sicians,15,58 possibly due to lack of knowledge, belief that the guide-
lines are already incorporated into practice or lack of relevance. 
Several consensus documents on IBD care advocate that MDTs 
receive specific training on guidelines.6,7
4. Discussion
As shown by the survey completed by the working group, specific 
IBD units are relatively uncommon in Europe and not all patients 
have predefined access to complementary specialists outside gas-
troenterology. Defined IBD treatment algorithms or structured pro-
cesses to derive therapeutic decisions are not in place in more than 
half of care settings, and structured support for IBD patients is only 
established in a few instances. This is particularly relevant, given that 
the respondents represented IBD specialists from centres with spe-
cific interest and reputation in IBD care. On a broad scale, it is likely 
that specialist IBD units and associated standards for IBD of care are 
vastly lacking throughout Europe.
It is clear that there is room for improvement in the quality of 
care that we offer to our patients with IBD. We believe that this 
can be achieved with well-considered and intentional changes to 
our existing gastroenterology departments to create optimised IBD-
specific units staffed by an IBD-focused MDT.
Although a substantial body of work has recently been published 
regarding quality indicators in IBD,22,48,49,50 there is currently a lack 
of evidence to guide optimisation of dedicated IBD units, particu-
larly with respect to the composition of the MDT, required physical 
resources, training, documentation, and patient support.
The recommendations presented here are largely based on expert 
experience and pragmatism, and supported where possible by pub-
lished evidence. Key points include the need develop an MDT with 
specific expertise in IBD, to instil processes that facilitate communica-
tion between different team members and patients, to provide clear 
documentation, and to invest in shared-care models of IBD manage-
ment. It should also be remembered that these recommendations have 
been generated by a group of physicians and represent medical priori-
ties that may be different from those of allied healthcare professionals 
or IBD patients. It is essential to consider the perspectives of these 
groups when engaging in strategies to optimise IBD centres.
In chronic diseases that lead to destruction of target organs, 
long-term outcomes can be vastly improved by disease management 
programmes. For example, care programmes for diabetes mellitus 
or arterial hypertension benefit from multidisciplinary therapeutic 
settings, therapeutic choice, and a defined disease management with 
ongoing diagnostic investigations and therapeutic adjustments.59,60 
It appears likely that IBD could also benefit from management 
programmes that include a ‘treat-to-target’ commitment. It will be 
instrumental to support this strategy with IBD centres that have a 
critical size and that meet the standards discussed in this article.
We recognise that there may be large discrepancies between the 
recommendations presented here and the reality of many hospitals 
and outpatient centres treating patients with IBD. However, although 
some centres may not have the resources to develop ideal settings, 
this need not be a barrier to taking small steps to optimise care in 
dedicated IBD units. Such change will require progressive leadership 
and willingness to challenge the status quo in order to provide better 
quality of care for our IBD patients.
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3.2.5.2 Patient education and support should be struc-
tured to complement the clinical care provided. 209/224 [94%] 
agreed
3.2.5.3 There should be shared decisionmmaking involving 
the gastroenterologist [and the MDT, if needed] and the IBD 
patient. 199/226 [88%] agreed
3.2.5.4 Patients should be informed about recognised IBD 
patient organisations. 208/219 [95%] agreed
Development and training of the MDT: recommendations:
3.2.6.1 The MDT should receive training on the unit’s 
agreed IBD guidelines. 207/220 [94%] agreed
3.2.6.2 The latest local and regional IBD guidelines should 
be incorporated into the unit’s practice guidelines, and these 
updates communicated to the MDT in a structured way. 
212/221 [96%] agreed
3.2.6.3 Representative members of the MDT should be 
encouraged to attend IBD-related meetings regularly. 189/213 
[89%] agreed
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